Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.

Abstract

BACKGROUND:

Psoriasis and inflammatory bowel diseases share common immunological pathomechanisms and therefore similar treatment options.

OBJECTIVE:

To assess already existing therapies and their efficacy versus adverse effects and paradoxical reactions in patients presenting with either disease or both.

DATA SOURCES:

A systematic search of the PubMed and Science.gov databases was performed for the period 2018-2020. Only articles in English were selected. Search terms included a combination of keywords: adalimumab, infliximab, etanercept, golimumab, certolizumab, ustekinumab, guselkumab, vedolizumab, secukinumab, ixekizumab, brodalumab, acitretin, cyclosporine, methotrexate, apremilast, mycophenolate mofetil, sulfasalazine, hydroxyurea, azathioprine, 6-thioguanine, tacrolimus, leflunomide and fumaric acid esters in combination with each of the following: paradoxical, psoriasis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis. Other potentially relevant articles were identified by manually checking the references of the included literature.

STUDY SELECTION:

Recent reviews and meta-analyses, pooled analyses, cohort studies, observational studies, care reports were all included.

CONCLUSIONS:

Psoriasis and IBD can be treated concurrently as they share common inflammatory pathways. TNF-α inhibitors and IL-12/23 have been successful in treating both psoriasis and IBD. IL-17 inhibitors are recognized treatments for psoriasis but have the potential to exacerbate IBD. Newer molecules require further clinical trials and real-life studies in order to confirm their efficacy and safety.

• Authors: Claudio Conforti, Caterina Dianzani, Iris Zalaudek, Michele Cicala, Paolo Persichetti, Roberta Giuffrida, Silviu-Horia Morariu, Nicoleta Neagu
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 33 Issue 3 Pg. 1279-1286 (May 2022) ISSN: 1471-1753 [Electronic] England
• PMID: 33074781 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Infliximab
• Ustekinumab
• Etanercept

Topics

• Etanercept (therapeutic use)
• Humans
• Inflammatory Bowel Diseases (complications, drug therapy)
• Infliximab (therapeutic use)
• Psoriasis (complications, drug therapy)
• Ustekinumab (therapeutic use)